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RESEARCH ARTICLE
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Abstract
Introduction: Microglial cells play an important role in the development of Alzheimer’s
disease (AD). People with Down syndrome (DS) inevitably develop AD neuropathology
(DSAD) by 40 years of age. We characterized the distribution of different microglial
phenotypes in the brains of people with DS and DSAD.
Methods: Autopsy tissue from the posterior cingulate cortex (PCC) from people with
DS, DSAD, and neurotypical controls was immunostained with the microglial marker
Iba1 to assess five microglia morphological types.
Results: Individuals with DS have more hypertrophic microglial cells in their white matter. In the gray matter, individuals with DSAD had significantly fewer ramified microglia
and more dystrophic microglia than controls and the younger individuals with DS. The
DSAD group also exhibited more rod-shaped and amoeboid cells than the AD group.
Discussion: Individuals with DS and DSAD show a microglial phenotype that distinguishes them from non-DS controls.
KEYWORDS

IBA-1, microglial morphology, neuroinflammation, posterior cingulate cortex, trisomy 21

1

INTRODUCTION

with social enrichment in DS has led to a significant extension in lifespan and increased quality of life, it has also increased the prevalence

Down syndrome (DS) or trisomy 21 is the most common genetic cause

of Alzheimer’s disease (AD). Further, the overexpression of the amy-

of intellectual disability. While improvements in medical care along

loid beta (Aβ) precursor protein (APP) gene, located on chromosome
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21, leads to an enhanced production of Aβ1 and is likely to be one
of the main causes for the increased risk of AD in this population.2–4
As a result, by 40 years of age the majority of people with trisomy
21 have sufficient numbers of Aβ plaques and neurofibrillary tangles
for a neuropathological diagnosis of AD. Notably, alterations in blood
and cerebrospinal fluid (CSF) biomarkers consistent with changes in
familial and sporadic AD are also found in people with DS.5–9 It is
estimated that 55% of individuals with DS between the ages of 40 to
49 show progressive cognitive impairment, while in individuals aged 60
to 69 this prevalence increases to 77%;10,11 thus, there is a temporal
disconnect between age when AD neuropathology is present and the
presence of clinical symptoms of dementia.11,12

HIGHLIGHTS
∙ Hypertrophic microglial cell numbers increase with age in
the white matter.
∙ Numbers of ramified microglia are lower with age in the
gray matter in people with DS and controls.
∙ People with DS and AD neuropathology have more dystrophic cells in the gray matter.
∙ People with DSAD have more rod-shaped and amoeboid
cells than controls.

A unique advantage to

studying AD in people with DS is that there is a distinct age-related pattern of neuropathology that may allow us to investigate and determine
the first appearance of alterations in specific pathways or cells.2
Neuroinflammation may be a key causative factor in the pathoDS.13–17

RESEARCH IN CONTEXT

In the frontal cortex of people with DS and

1. Systematic Review: We reviewed the literature using

dementia, there is a dysregulation of numerous genes related to Aβ

PubMed. We searched for research studies describing

and tau biology, as well as other fundamental pathways related to

microglial changes and characterization in autopsy tissue

intracellular signaling, cell homeostasis, and death, and the cholinergic

from brains of people with Down syndrome (DS) and/or

and glutamatergic systems, among others, suggesting a specific genetic

Alzheimer’s disease (AD), and these have been appropri-

genesis of AD in

profile implicating cortical dysfunction in demented individuals with

ately cited.

DS.18 Interestingly, the dysregulation of immune-related genes indi-

2. Interpretation: Our findings demonstrate that people

cate an inflammatory state in the adult brain, as these genes are not

with DS, and particularly those with Alzheimer’s disease

altered in fetal brains, and could be directly linked to the development

pathology (DSAD), present a microglial phenotype pat-

of AD pathology in DS.19 There are at least six genes on chromosome

tern that distinguishes them from non-DS controls. In

21 that may contribute to increased inflammation in DS.16 Both human

DSAD there are more dystrophic and fewer ramified

DS and DS mouse models present with marked neuroinflammation,

microglial cells, suggesting more damage to microglia.

with the activation of both microglia and astrocytes.14,20,21 In adults

Further, it reinforces the differences seen in individ-

with DS there is a correlation between inflammatory markers and

uals with DS with regard to their neuroinflammation

other AD biomarkers as well as an increase in the circulating levels of

response.

inflammatory cytokines in blood.22,23 In previous autopsy studies, we

3. Future Directions: More studies are necessary to fully

noted that the inflammatory phenotype of people with DS is different

evaluate the role of each specific microglial phenotype in

from age-matched neurotypical controls reflecting an increase in

DS, and to understand the microglial pathways that con-

pro-inflammatory gene expression like interleukin (IL)-6 and IL-12.

tribute to the development and progression of AD in indi-

In the presence of AD neuropathology in the DS (DSAD) brain, there

viduals with DS.

is additional inflammation present that overlaps with that seen in
sporadic AD.15 However, elevated CD86 and FcgR1 is observed in
DSAD, which is different from sporadic AD, and suggests extravasation
of serum proteins into the brain that may promote the formation of

cytoplasm and without processes. Changes in microglial morphology

immune complexes. Consistent with increased inflammation in DS, our

and motility can be exacerbated in AD and other pathologies, which

initial studies of microglial activation, using HLA-DR immunostaining,

reflect the functional state of the cell, and potentially contribute to the

showed higher microglial loads in DSAD relative to DS and controls,15

development and progression of the disease.28,29

consistent with reports in sporadic AD.24

Microglial morphology in DS, particularly in people with DSAD,

Microglial cells play an important role in AD development, with evi-

remains largely unexplored. The first description of differences in

dence evolving from studies of their close interaction with plaques and

microglia in DS reported significantly more IL-1 positive microglia

tangles, an increased risk of AD due to polymorphisms in microglial-

in brain tissue from young people with DS relative to age-matched

expressed genes such as TREM2 and CD33, as well as changes in

controls (postnatal to 41 years of age).30 Moreover, a reduced number

their morphology in the presence of AD

pathology.25–27

Microglia

of resting microglia is accompanied by increased dystrophic microglial

morphology in humans can range from ramified to amoeboid cells.

cells in a small study of autopsy cases with DS over 40 years of age.31

While a ramified shape is characterized by a small, round cell body

Thus, the current study was intended to expand upon these studies

with extended long branching processes, amoeboid microglia are at

and explore microglial morphology responses in the brains of people

the extreme end of the spectrum with a large round cell body, rich in

with DS with or without AD across the lifespan, with a focus on the
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TA B L E 1

Case characteristics for posterior cingulate cortex tissue obtained from brain banks
YC

DS

MC

DSAD

AC

AD

N

11

10

10

17

6

6

Age at death, years

17.89
(11.83)

19.5
(15.54)

53.5
(6.65)

57.00
(8.28)

78.67
(2.16)

78.83
(1.83)

Male/female, n/n

9/2

7/3

6/4

8/9

3/3

4/2

Post mortem interval (PMI), hours

20.45
(5.05)

19.3
(6.15)

16.2
(6.78)

5.98
(6.41)

9.00
(6.54)

12.86
(10.13)

Abbreviations: AC, aged control; AD, sporadic Alzheimer’s disease; DS, Down syndrome; DSAD, Down syndrome with neuropathological Alzheimer’s disease;
MC, middle-aged control; YC, young control.
Note: Mean + standard deviation.

posterior cingulate cortex (PCC). The rationale for selecting the PCC

group; n = 10), aged controls (AC; age-matched to AD group; n = 6),

is three-fold. First, older individuals with DS show lower glucose

Down syndrome (DS, n = 10), Down syndrome with neuropatholog-

Second,

ical AD (DSAD, n = 17), and sporadic AD (AD, n = 6). DSAD are DS

the PCC, along with the precuneus and posterior parietotemporal

cases that had sufficient neuropathology for a post mortem diagnosis

lobes, is also one of the earliest sites of reduced glucose metabolism

of AD, according to Hyman et al.35 Because people with DSAD come

(fluorodeoxyglucose positron emission tomography) before the

to autopsy at younger ages than those with sporadic AD, we were not

appearance of symptoms in sporadic AD, which can lead to neuronal

able to match for age between these two groups. All control cases were

and synaptic loss.33 Third, neuronal health biomarkers in this region

selected to match for post mortem interval (PMI) to the DS, DSAD, and

are lower as measured by magnetic resonance spectroscopy, while

AD cases. Our groups contained both males and females, but due to

glial biomarkers are significantly higher, in demented adults with DS.34

the limited availability of cases, we were not able to match for sex

To further characterize microglia phenotypic changes in DS, we used

across groups. Clinical data were not incorporated into the present

Iba1 (ionized calcium binding adaptor molecule 1) immunostaining

study.

metabolic rates in the PCC relative to their control

groups.32

that labels all microglia cells and their processes, allowing for a better
characterization of their morphology. Thus, the aim of this study was to
characterize the distribution of different microglial phenotypes in the

2.2

Immunohistochemistry

brains of people with DS and DSAD relative to age-matched controls,
and late onset AD.

Tissue was sectioned on a vibratome (Leica Biosystems, Buffalo Grove,
Illinois, USA) at 50 μm. Sequential sections were collected and stored in
PBS with 0.02% sodium azide until used. Following standard immuno-

2

METHODS

histochemistry protocols and using Iba-1 antibody (Abcam, Cambridge, Massachusetts, USA; 1:800) the sections were incubated in

2.1

Human tissue samples

the primary antibody overnight and followed by incubation in an
anti-rabbit secondary antibody (Vector Laboratories, Burlingame, Cal-

Fixed tissue samples were acquired from the PCC (Brodmann area 23

ifornia, USA). This was followed by amplification of the signal using

and 31) from the tissue repositories located at the Alzheimer’s Disease

an avidin-biotin complex peroxidase kit, and 3,3′ diaminobenzidine

Research Center at the University of California Irvine, the NIH Neu-

substrate kit. After immunohistochemistry, each tissue section was

roBioBank, and the University of Kentucky Alzheimer’s Disease Cen-

mounted on a glass slide and coverslipped with Depex mounting media.

ter. Human tissue collection and handling adhered to the University

All tissue sections were immunostained within a single experiment to

of Kentucky and University of California, Irvine, Institutional Review

reduce variability.

Board guidelines. Neuropathologic diagnosis of AD was in accordance
with current National Institute on Aging-Alzheimer’s Association (NIAAA) guidelines.35,36 Cases from the University of California Irvine

2.3

Image analysis

were fixed in 4% paraformaldehyde, while cases from the NIH NeuroBioBank and the University of Kentucky were fixed in 10% formalin. A

The Aperio ScanScope XT digital slidescanner was used to scan the

solution of phosphate buffered saline (PBS) with 0.02% sodium azide

entire slide at 20x magnification. The Aperio ImageScope (v11.1.2.752)

was used for long-term storage. No information regarding the length

software was used to draw five random 250 × 250 micron boxes in the

of fixation is available.

white matter (WM) and five random 250 × 250 micron boxes in the

Six autopsy groups were included in this study (Table 1): young

gray matter (GM) for each tissue section (Figure 1A). Five microglia

controls (YC; age-matched to young DS group; n = 10), middle-aged

morphological types were assessed, as defined in previous work and

controls (MC; age-matched to Down syndrome-Alzheimer’s disease

illustrated in Figure 1B–F37–40 : (B) ramified microglia, which have thin,
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F I G U R E 1 Microglia morphologies evaluated in the posterior cingulate cortex, and microglia cell counts in the Alzheimer’s disease (AD) brain.
A, Characterization of microglia was performed in five random 250 × 250 micron boxes in the white matter and five random 250 × 250 micron
boxes in the gray matter for each tissue section Scale: 3 μm. Five microglia morphologies were analyzed: (B) ramified microglia, which have thin,
branched processes to actively “survey” changes in their environment; (C) hypertrophic microglia (also known as activated microglia), which may
have enlarged, short processes and thicker bodies; (D) dystrophic microglia, that present fragmented or “beaded” processes possibly due to
microglial dysfunction as a result of aging; (E) rod-shaped microglia, that have elongated nuclei, few processes, and are most notable in chronic
disorders; (F) amoeboid microglia, which have a round body, lack processes, and appear in response to acute destruction of central nervous system
tissue. Scale: 5 μm. G–K, In the white matter, no significant changes were observed in any of the microglial phenotypes analyzed. In the gray matter,
a significant reduction was observed in the number of ramified cells in the AD group, while the number of dystrophic cells was increased, compared
to aged controls. Data are presented as mean ± standard error of the mean, * P ≤ 0.05 (Student’s t test)

5 of 12
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branched processes that are thought to actively “survey” changes in

of comparing DSAD with middle-aged controls without controlling for

their environments; (C) hypertrophic microglia (also known as acti-

age is the most appropriate way to conduct these analyses. Comparing

vated microglia), which may have enlarged, short processes and thicker

DS to DSAD while controlling for age would eliminate all possible out-

bodies; (D) dystrophic microglia that have fragmented or “beaded” pro-

comes as the DSAD are always older than the DS group.

cesses possibly due to microglial dysfunction due to aging

41,42 ;

(E)

Therefore, in PCC WM, the number of hypertrophic microglia is con-

rod-shaped microglia that have elongated nuclei, few processes, and

sistently higher in DS groups (main effect of genotype, independent of

are most notable in chronic disorders; and (F) amoeboid microglia that

age [F(1,46) = 6.239, P = .016]), but none of the other microglial phe-

have a round body, may lack processes, and appear in response to

notypes are significantly different (Figure 2A).

acute destruction of central nervous system tissue. The number of ram-

In the GM, both age group and genotype have different effects

ified, hypertrophic, dystrophic, rod-shaped, and amoeboid microglia

for individual microglial phenotypes. Comparing ramified microglial

in each annotation box was counted by hand and averaged for each

counts, we find a main effect of age group independent of genotype

case, separating WM and GM. The categorical analysis used to quan-

(F[1,46] = 5.827, P = 0.020), reflecting an overall decrease in the num-

tify the microglia expanded upon previously established guidelines and

bers of ramified microglial cells independent of the presence of DS

figures.38,43,44 Counts were made by two investigators blinded to all

(Figure 2B). While the number of ramified cells is lower in cases over

samples groups and case histories. Cohen’s κ was run to determine

40 years of age, dystrophic microglia counts are higher, demonstrat-

whether there was agreement between investigators.

ing also a significant effect of age independent of genotype in the gray
matter of PCC (F[1,46] = 4.488, P = 0.04). The amoeboid cell quantification demonstrate a main effect of genotype overall (F[1,46] = 5.645,

2.4

P = 0.022) as well as age (F[1,46] = 3.868, P = 0.056), and a significant

Statistics

interaction between age and genotype (F[1,46] = 6.449, P = 0.015). The
IBM SPSS Statistics Software (Version 24) was used for statistical anal-

number of amoeboid cells was higher in DS overall and primarily driven

ysis. Overall group differences were assessed for the GM and WM

by high numbers in DSAD PCC.

separately using a two-way analysis of variance to examine interactions between age groups and genotype (DS vs non-DS). Comparisons
between two groups were made using Student’s t test. Differences

3.3

Microglial morphology in DS

between means were considered significant at P ≤ .05. Graphs were
generated using GraphPad Prism software version 8.0, with values

Given that we cannot separate age from the presence of AD neu-

expressed as mean ± standard error of the mean.

ropathology in DS, we compared four groups divided between genotype (DS vs control) and age group (<40 vs >40 years), reflecting
absence and presence of AD neuropathology, respectively (Figure 3).

3

RESULTS

No significant differences were found in the WM between the
groups (Figure 3A - E). In the GM, DSAD was associated with the fewest

3.1
Microglial phenotypes in AD versus
age-matched controls

numbers of ramified microglial cells, both in comparison to MC (P =
0.023) or DS (P = 0.009) (Figure 3A). While the number of ramified cells
is lower in cases over 40 years of age, dystrophic microglia counts are

Quantification of Iba1-positive cells in the GM of patients with AD

higher in the DSAD group when compared to the DS group (P = 0.007)

demonstrate a significant decrease of ramified cells, while dystrophic

and middle-aged controls (P = 0.019; Figure 3C). The average num-

cells are increased, compared to age-matched controls (Figure 1G,

ber of rod-shaped cells is consistently low, so the apparent increase in

I, respectively), consistent with previous reports.38,40,42,45 Also, the

DSAD groups is not sufficient to achieve statistical significance (Figure

numbers of hypertrophic microglia did not vary significantly across

3D). Counts for amoeboid microglia are also consistently low across all

groups (Figure 1H) nor did the numbers of rod-shaped or amoeboid

groups; however, higher numbers of amoeboid microglia are present in

cells (Figure 1J, K), highlighting the robustness and reliability of the

a subset of our DSAD cases . While we found a significant increase in

methodology used in this study.

the number of amoeboid cells overall in the DSAD group in comparison
to the DS group (P = 0.008) and middle-aged controls (P = 0.003), the
numbers of these cells are low and this result needs to be cautiously

3.2
Microglial morphology differences with age
and genotypes

interpreted (Figure 3E).

Age and the presence of AD pathology are completely intertwined in

3.4
Microglial phenotype comparing DSAD
and sporadic AD

DS. By 40 years of age, virtually all adults with DS have enough neuritic
plaques and neurofibrillary tangles for a diagnosis of AD pathology.2,46
Deposition of Aβ happens decades earlier in DS, compared to agedmatched controls and AD

brains.1

Thus, we believe that our rationale

No significant differences are observed for any of the microglial phenotypes in the WM comparing DSAD to AD (Figure 4). Further, the
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F I G U R E 2 Distribution of microglia phenotypes across different groups in white and gray matter. The average number of microglia in each of
the five classifications according to each group in the white (A) and gray (B) matter, demonstrating the age and genotype effects related to the
morphology of cells. Data are presented as means. A, In the white matter, hypertrophic microglia increase as a main effect of genotype. B, In the
gray matter, the age effect is significant for ramified and dystrophic cells. Amoeboid cells have an effect of age, genotype, and a significant
interaction between these factors
numbers of ramified, hypertrophic, and dystrophic microglia were sim-

4

DISCUSSION

ilar across groups (Figure 4A–C). There are, however, individual DSAD
cases that have higher numbers of ramified and dystrophic microglia.

The aim of this study was to characterize the distribution of differ-

Consistent with the literature,38,47 few rod-shaped microglia were

ent microglial phenotypes in the brains of people with DS and DSAD.

found, thus the average counts are relatively low. Interestingly, in the

We used autopsy tissue from the PCC to characterize microglia in the

GM of DSAD cases there are more rod-shaped cells (P = 0.0387) com-

white and gray matter by manually assessing morphology based upon

pared to AD cases (Figure 4D). Moreover, DSAD also presents with

immunostaining with Iba1, a marker of all microglia cells and their pro-

more amoeboid cells than the AD group (P = 0.0009; Figure 4E).

cesses.

MARTINII ET AL.
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F I G U R E 3 Characterization of microglia phenotypes in the white and gray matter in Down syndrome (DS) groups. Microglial counts are
provided for the white (WM) and gray matter (GM) for (A) ramified, (B) hypertrophic, (C) dystrophic, (D) rod-shaped, and (E) amoeboid
morphologies. No significant changes were observed in any of the microglial phenotypes analyzed in the white matter. In the gray matter, the DS
with neuropathological Alzheimer’s disease group presented a significant reduction in the number of ramified cells and an increase in the counts of
dystrophic and amoeboid cells, when compared to DS and middle-aged control groups. Data are presented as mean ± standard error of the mean, *
P ≤ .05 (two-way analysis of variance)

In our study, we observe a significant genotype effect (DS vs non-

potentially elicit hypertrophied microglial cells observed in the WM

DS) in the number of hypertrophic microglia in the WM. Hypertrophic

in our study.49,50 Our results do not demonstrate significant changes

microglia have enlarged, short processes, and thicker bodies, and are

in any of the other microglial phenotypes in the WM, which could be

thought to be actively responding to injury.38,40 This increase in hyper-

due to lower numbers overall, leading to a floor effect. Interestingly,

trophic microglia contrasts with other published findings on microglia

we observed an increase, although not significant, in the number of

in DS, which show individuals with DS having fewer hypertrophic

dystrophic cells in the WM of all groups, including young controls.

microglia than controls.31 However, these studies were focused on the

Microglia is a dynamic cell that can adapt and change its morphology

GM in the temporal cortex, highlighting the importance of examining

according to different pathological situations.51 In our study, different

both the white and gray matter. In addition to a unique inflammatory

causes of death could potentially explain the pattern changes observed

response, people with DS also show a significant reduction in WM

in young groups; unfortunately, this information is not available for

integrity compared to controls.48 Moreover, significant vascular

further investigation. Observations in our cases with DS are consistent

pathology is also observed with increasing age in DS, which could also

with studies in other autopsy series of AD. Recent studies shed some
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F I G U R E 4 Down syndrome with neuropathological Alzheimer’s disease (DSAD) presents more rod-shaped and amoeboid cells than AD.
Differences in microglial counts for the white matter (WM) and gray matter (GM) between DSAD and AD groups are shown for (A) ramified, (B)
hypertrophic, (C) dystrophic, (D) rod-shaped, and (E) amoeboid phenotypes. While no significant changes were seen in the WM, the DSAD group
presented significant increase in the number of rod-shaped and amoeboid microglia cells in the GM, compared to AD alone. Data are presented as
mean ± standard error of the mean, * P ≤ 0.05 (Student’s t test)

light into aspects of WM changes during aging, where activated
changes,52

We found a significant reduction of the number of ramified

and microglia

microglial cells in the GM with increasing age, as well as a significantly

proteins increase in an age-dependent manner already in middle-aged

lower number of ramified microglial phenotype in the AD group.

people.53 Even more interesting is the detection of increased microglia

Ramified microglia, which have thin, branched processes are thought

microglia respond to age-related pathologic

activity in the WM of human post mortem early-onset AD (EOAD) brain

to be actively “surveying” changes in their environment.37,39 Previous

tissue, detected through non-invasive positron emission tomography

studies also found reduced ramified microglia in individuals with DS

imaging using [11C]-(R)-PK11195, a ligand that binds to activated

relative to age-matched controls,31 and fewer ramified microglia

microglia.53

Findings from other studies demonstrate a relationship

are also observed in individuals with non-DS dementia (including AD,

between the increase of activated microglia in the WM and GM

hippocampal sclerosis of aging, hippocampal sclerosis of aging with AD,

atrophy in other dementias,54 suggesting abnormalities in WM as an

and dementia with Lewy bodies) than age-matched controls without

early event preceding GM atrophy, especially in EOAD.55

dementia.38

MARTINII ET AL.
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F I G U R E 5 Group specific patterns in Iba1 microglia staining. Representative images of microglia morphologies observed in the white (A) and
gray (B) matter of young controls (A1, B1), middle-aged controls (A2, B2), aged controls (A3, B3), Down syndrome (A4, B4), Down syndrome with
neuropathological Alzheimer’s disease (A5, B5), and AD (A6, B6), respectively. Scale: 50 μm
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Descriptions of rod-shaped microglia, which present elongated

Overall, individuals with DS, particularly those with DSAD, have a

nuclei, few processes, and are most notable in chronic disorders,

distinct microglial phenotype pattern. In DSAD, there is a shift toward

are sparse in the literature. Based on previous studies showing an

the presence of higher numbers of dystrophic microglial cells and fewer

increase in rod-shaped microglia with age38,47 and the presence of

ramified microglial cells suggesting fewer resting state microglia and

rod cells in the hippocampus of people with DS56 we hypothesized

more damage to microglia, as well as increased amoeboid cells. Fur-

that we would see an increase in rod-shaped microglia with age in our

ther, individuals with DS appear to have important microglial changes

controls and DS autopsy cases. However, we only found a significant

that could be related to the development and progression of AD. Our

increase in rod-shaped microglia in our DSAD cohort in comparison

data suggest that microglial changes progress gradually over time as

to AD. The function of these cells remains under investigation, but

DS individuals are aging and, more importantly, provide specific infor-

it is believed that they could provide neuroprotection to neurons

mation related to the presence of AD in DS. These data reinforce the

support.57,58

The role of rod-shaped microglia in aging

differences in the neuroinflammation phenotype seen in individuals

and the development of AD in DS is still unclear and encourages

with DS and, given the large variety of inflammatory genes located on

more studies; however, our findings suggest that DSAD is associated

chromosome 21, suggest that these different gene expression profiles

with a microglial phenotype that distinguishes them from non-DS

could also be impacting the morphology of microglia cells, and conse-

cases.

quently, their response to the presence of AD pathology. Neuropatho-

and trophic

Amoeboid microglia are most commonly found in the developing

logical observations from autopsy cases with DS allows us to directly

brain, before transforming into ramified microglia.39,59 They have an

assess early events in AD, addressing a critical gap in our knowledge

increased level of motility, facilitated by their reduced and retracted

regarding early events, which are targetable, in sporadic AD pathogen-

processes, and are phenotypically very similar to macrophages found

esis.

in the rest of the body.60 It is still unknown whether these microglia
are senescing microglia found in the brain, or if they originate from

ACKNOWLEDGMENTS

monocytes entering the brain in response to injury.37 We found that

This study was supported by grants from the National Institutes

our DSAD cases had significantly more amoeboid microglia than age

of Health (NIH; NIH/NICHD HDR01064993 [E.H., E.A., F.A.S.]).

matched controls or young individuals with DS. It is possible that mono-

Autopsy cases from UC Irvine were supported by the NIH (NIH/NIA

cytes from the blood are entering the brains of people with DS as

P50AG16573 [I.T.L., E.D.]), R01AG21912 (E.D., I.T.L.), U01AG051412

vascular neuropathology may lead to small microhemorrhages in the

(I.T.L, E.D, EH), and Brightfocus Grant #CA2018010 (E.H.). We also

brain49,50 and the presence of more amoeboid microglial cells; how-

would like to thank the NIH NeuroBioBank for a subset of the autopsy

ever, further work needs to be done to explore the clinical significance

cases used in this study (https://neurobiobank.nih.gov/). The authors

of amoeboid microglia in DSAD.

would also like to thank Morgan Siever for her collaboration through-

Finally, and most importantly, dystrophic microglia counts are sig-

out the study.

nificantly increased in older individuals with DS (age effect), and in
AD. The concept of a hypofunctional microglia, as opposed to acti-

AUTHOR CONTRIBUTIONS

vated, came from morphological analysis of Iba1-positive microglia

Conception and design of the study: Alessandra C. Martini, Alex M.

in autopsy samples from aged humans, where dystrophic microglia

Helman, Frederick A. Schmitt, Elizabeth Head. Data acquisition and

preceded neurofibrillary pathology in AD.61 This suggested that the

analysis: Alessandra C. Martini, Alex M. Helman, Katie L. McCarty.

loss of microglial function might be as important as the activation

Manuscript preparation: Alessandra C. Martini, Alex M. Helman, Ira T.

of a toxic, reactive cell. Other studies that aimed to quantify and

Lott, Eric Doran, Frederick A. Schmitt, Elizabeth Head. Study supervi-

characterize microglial morphology in AD also found increased dys-

sion: Elizabeth Head.

trophic cells.38,40,42,45 Individuals with DSAD showed a higher number of dystrophic microglia than the AD group, albeit their numbers

CONFLICTS OF INTEREST

did not reach statistical difference. Additionally, young controls with

The authors declare no competing interests.

DS have high numbers of dystrophic microglia in the WM, suggesting
that this region in the DS brain is particularly vulnerable to degeneration, and that some aspects of aging might be accelerated in this
population.62,63 Dystrophic microglia have fragmented or “beaded”
processes that may be the result of microglial dysfunction or senescence due to aging or AD neuropathology, and are thought of as
important markers for AD pathology. It is well accepted that human
microglial processes shorten with age, leading to a reduced arborization area and reduced capacity for GM surveillance.27,51 Importantly,
tau-positive neurons are associated with dystrophic microglia, supporting a fundamental role for lack of microglial support in the disease
progression.61
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